We are SO EXCITED to announce that we’ve teamed up with Sherry Pollex, ovarian cancer survivor, to launch the Teal Appeal: A campaign dedicated to letting people know that ovaries … Continued
It’s Wear Teal Day! The ladies of OCNA are out and about today getting creative with TEAL! Show us your TEAL—the awareness color for ovarian cancer—and tell everyone you see … Continued
Our Survivors Teaching Students: Saving Women’s Lives® program has educated tens of thousands of future health professionals to recognize the signs of ovarian cancer. We need your help to ensure … Continued
Check out this guest post by Alan D. D’Andrea, MD, and Elizabeth M. Swisher, MD from the SU2C-OCRF-OCNA-NOCC Dream Team that originally appeared on Cancer Research Catalyst, the official blog of the American Association for Cancer Research, the Scientific Partner of Stand Up 2 Cancer. September is Ovarian Cancer Awareness Month, when we scientists and advocates renew our determination to find new solutions to this devastating disease. This year we are pleased to have seen some encouraging signs. At the Annual Meeting of the American Association for Cancer Research (AACR) in April, scientists reported that a combination of two drugs, olaparib and BKM120, showed clinical benefit for women with high-grade serous ovarian cancer (as well as women with triple-negative breast cancer). Click plus sign to read on.
Ovarian Cancer Research Fund’s Luxury Shopping Event to be held at Grand Canal Shoppes at The Venetian & The Palazzo and Fashion Show, September 19-20 Las Vegas, NV – Ovarian … Continued
"Ovarian cancer is difficult to detect early -- there is no simple and reliable way to screen for it and symptoms are often not clear until later stages. By recognizing possible warning signs and unexplained changes, women can increase their likelihood of detecting ovarian cancer in its early stages when treatment is most effective and the chances for recovery are greatest. To bolster these efforts, my Administration has continued to invest in innovative research to improve early detection and treatment of ovarian cancer, and we are working hard to increase public awareness among women about all types of gynecological cancers." -President Barack Obama To read more, click the plus sign.
(August 26, 2015) Women with epithelial ovarian cancer who happened to be taking nonselective beta-blockers for hypertension survived longer than those who were not taking the drugs, according to a … Continued
(August 21, 2015) A study published online in JAMA Oncology this month shows that screening women with a suspected risk of hereditary breast or ovarian cancer with a multigene panel … Continued
(August 19, 2015) Deleterious mutations in RAD51C and RAD51D genes are associated with increased risk of epithelial ovarian cancer (EOC), according to a study published online Aug. 10 in the … Continued
(August 19, 2015) Whereas chemotherapy kills cancer cells only while it is being administered, immunotherapy can lead to an adaptive immune response that persists long after treatment is ceased. By … Continued
(August 17, 2015) A study from the University of California, Davis found that one-third of women with ovarian cancer survive at least 10 years after diagnosis. The study, published in … Continued
On August 3, 2015 the New York Times published an article about the use of IP chemotherapy in the treatment of ovarian cancer. Our CEO, Calaneet Balas joined with Ovarian Cancer Research Fund CEO, Audra Moran, to write a response to the New York Times. Click the plus sign to see their Letter to the Editor.
Get email updates about research news, action alerts, and ways to join the fight.
